• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Gain Therapeutics Inc.

    4/28/26 4:47:26 PM ET
    $GANX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $GANX alert in real time by email
    DEFA14A 1 ganx-20260428xdefa14a.htm DEFA14A

    ​

    ​

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    ​

    SCHEDULE 14A

    ​

    Proxy Statement Pursuant to Section 14(a) of
    the Securities Exchange Act of 1934

    (Amendment No.__)

    ​

    ​

    ​

    Filed by the Registrant

    ☒

    Filed by a party other than the Registrant

    ☐

    ​

    Check the appropriate box:

    ​

    ​

    ☐

    Preliminary Proxy Statement

    ☐

    Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

    ☐

    Definitive Proxy Statement

    ☒

    Definitive Additional Materials

    ☐

    Soliciting Material under § 240.14a-12

    ​

    GAIN THERAPEUTICS, INC.

    (Name of Registrant as Specified In Its Charter)

    ​

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

    Payment of Filing Fee (Check all boxes that apply):

    ​

    ​

    ☒

    No fee required

    ☐

    Fee paid previously with preliminary materials

    ☐

    Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

    ​

    ​

    00


    GRAPHIC

    GAIN THERAPEUTICS, INC. Mr AB Sample Sample Street Sample Town Sampleshire, XXX XXX Important Notice Regarding the Internet Availability of Proxy Materials for the Annual Meeting of Stockholders to be held on June 24, 2026 at 8:30 a.m. Eastern Time. This communication is not a form of voting and presents only an overview of the more complete proxy materials that are available to you on the Internet. We encourage you to access and review all of the important information contained in the proxy materials before voting. The Proxy Statement and Annual Report are available at https://web.viewproxy.com/GANX/2026 If you want to receive a paper or email copy of these documents, you must request one by following the instructions below on or before June 10, 2026 to facilitate timely delivery. There is no charge to you for requesting a copy. Important information regarding the Internet availability of the Company’s proxy materials, instructions for accessing your proxy materials and voting online, and instructions for requesting paper or e-mail copies of your proxy materials are outlined in this Notice. You must use the 11-digit Virtual Control Number located in the box to attend the Annual Meeting virtually, to vote via Internet, or to request proxy materials. CONTROL NUMBER STOCKHOLDERS ARE CORDIALLY INVITED TO ATTEND THE ANNUAL MEETING. To the Stockholders of GAIN THERAPEUTICS, INC. The 2026 Annual Meeting of Stockholders of Gain Therapeutics, Inc. will be on June 24, 2026 at 8:30 a.m. Eastern Time. Annual Meeting of Stockholders to be held at the offices of Lowenstein Sandler LLP, 1251 Avenue of the Americas, Floor 17, New York, New York 10020. The Board recommends a vote “FOR” all nominees set forth in Proposal 1 and “FOR” Proposal 2. Proposal 1 - ELECTION OF DIRECTORS (1) Gene Mack (2) Khalid Islam, Ph.D. (3) Dov Goldstein, M.D. (4) Hans Peter Hasler (5) Gwen Melincoff (6) Claude Nicaise, M.D. (7) Jeffrey Riley Proposal 2 - To ratify Ernst & Young AG as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. NOTE: To conduct any other business properly brought before the Annual Meeting.

    GRAPHIC

    Internet: Go to https://web.viewproxy.com/GANX/2026 Have the 11-digit Virtual Control Number available when you access the website and follow the instructions. Telephone: Call 1-877-777-2857 Toll Free E-Mail: By e-mail at: requests@viewproxy.com * If requesting material by e-mail, please send a blank e-mail with the company name and your 11-digit Virtual Control Number in the subject line. No other requests, instructions, or other inquiries should be included within this email request. The Securities and Exchange Commission rules permit us to make our proxy materials available to our stockholders via the Internet. Material for this Annual Meeting and future meetings may be requested by one of the following methods: Via Internet prior to the Annual Meeting: Go to www.AALvote.com/GANX Have your 11-digit Virtual Control Number available and follow the prompts. • Your electronic vote prior to the Annual Meeting authorizes the named proxies to vote your shares in the same manner as if you marked, signed, dated, and returned a proxy card. Via Mail: Request a paper copy of the materials which includes a proxy card. Follow the instructions on the proxy card for voting by mail. Via Telephone: Call 1-866-804-9616 Use any touch-tone telephone to vote your proxy. Have your 11-digit Control Number available. Follow the voting instructions to vote your shares. In Person: Annual Meeting of Stockholders to be held in person on June 24, 2026 at 8:30 AM Eastern time at the offices of Lowenstein Sandler LLP, 1251 Avenue of the Americas, Floor 17, New York, New York 10020. VOTING METHODS GAIN THERAPEUTICS, INC. CONTROL NUMBER

    Get the next $GANX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $GANX

    DatePrice TargetRatingAnalyst
    3/7/2025$12.00Sector Outperform
    Scotiabank
    12/6/2024$7.00Buy
    ROTH MKM
    8/14/2024$8.00Outperform
    Oppenheimer
    11/3/2021$21.00Buy
    B. Riley Securities
    More analyst ratings

    $GANX
    SEC Filings

    View All

    Gain Therapeutics Inc. filed SEC Form 8-K: Other Events

    8-K - Gain Therapeutics, Inc. (0001819411) (Filer)

    5/26/26 9:26:00 AM ET
    $GANX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Gain Therapeutics Inc.

    10-Q - Gain Therapeutics, Inc. (0001819411) (Filer)

    5/11/26 4:08:30 PM ET
    $GANX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Gain Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Gain Therapeutics, Inc. (0001819411) (Filer)

    5/11/26 4:05:35 PM ET
    $GANX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GANX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Gain Therapeutics Presents Positive Interim Data from Phase 1b Clinical Study of GT-02287 at 3rd International GBA1 Meeting 2026

    MDS-UPDRS scores remained stable and durable across overall study population after 150 days of treatment with GT-02287 Differential response between participants with low and high baseline GluSph continues, with a difference of 4.8 points in the sum of MDS-UPDRS Part II and Part III scores between the two groups at Day 150 Most common benefits reported by study participants include meaningful improvements in specific functional areas such as smell and taste, sleep, and balance or gait BETHESDA, Md., May 26, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (NASDAQ:GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of the next ge

    5/26/26 8:00:00 AM ET
    $GANX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Gain Therapeutics Reports Financial Results for First Quarter 2026 and Provides Corporate Update

    BETHESDA, Md., May 11, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (NASDAQ:GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today reported financial results for the quarter ended March 31, 2026, and provided a corporate update. "The first quarter of 2026 marked another exciting quarter for Gain, as we continued to build on the important advancements achieved in 2025 related to both the scientific understanding and clinical development of our lead candidate GT-02287, in development for the treatment of Parkinson's disease with or without a GBA1 mutation. This is

    5/11/26 7:00:00 AM ET
    $GANX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Gain Therapeutics Announces Oral Presentation at 3rd International GBA1 Meeting 2026

    BETHESDA, Md., April 24, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (NASDAQ:GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced an oral presentation at the 3rd International GBA1 Meeting 2026, being held May 22-23, 2026, in Phoenix, AZ. Details of the oral presentation are as follows:Presentation Title: "An update on the development of the GCase modulator GT-02287 for Parkinson's disease"Presenter:Jonas Hannestad, M.D., Ph.D., Chief Medical Officer of GainSession Name:In the pipeline: updates from pharma on ongoing preclinical studies and clinical

    4/24/26 8:30:00 AM ET
    $GANX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GANX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CFO and Interim CEO Mack Gene bought $14,544 worth of shares (14,400 units at $1.01) (SEC Form 4)

    4 - Gain Therapeutics, Inc. (0001819411) (Issuer)

    8/12/24 5:23:31 PM ET
    $GANX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Executive Chairman Islam Khalid bought $49,940 worth of shares (50,000 units at $1.00) (SEC Form 4)

    4 - Gain Therapeutics, Inc. (0001819411) (Issuer)

    8/12/24 5:23:30 PM ET
    $GANX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Richman Eric I bought $20,670 worth of shares (17,000 units at $1.22), increasing direct ownership by 6% to 289,629 units (SEC Form 4)

    4 - Gain Therapeutics, Inc. (0001819411) (Issuer)

    7/1/24 5:00:27 PM ET
    $GANX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GANX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Mack Gene

    4 - Gain Therapeutics, Inc. (0001819411) (Issuer)

    3/26/26 8:01:00 PM ET
    $GANX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Fuggetta Gianluca

    4 - Gain Therapeutics, Inc. (0001819411) (Issuer)

    3/26/26 8:00:11 PM ET
    $GANX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Islam Khalid

    4 - Gain Therapeutics, Inc. (0001819411) (Issuer)

    6/25/25 5:30:23 PM ET
    $GANX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GANX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Scotiabank initiated coverage on Gain Therapeutics with a new price target

    Scotiabank initiated coverage of Gain Therapeutics with a rating of Sector Outperform and set a new price target of $12.00

    3/7/25 8:20:06 AM ET
    $GANX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ROTH MKM initiated coverage on Gain Therapeutics with a new price target

    ROTH MKM initiated coverage of Gain Therapeutics with a rating of Buy and set a new price target of $7.00

    12/6/24 7:48:38 AM ET
    $GANX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Oppenheimer resumed coverage on Gain Therapeutics with a new price target

    Oppenheimer resumed coverage of Gain Therapeutics with a rating of Outperform and set a new price target of $8.00

    8/14/24 7:36:01 AM ET
    $GANX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GANX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Gain Therapeutics Inc.

    SC 13G/A - Gain Therapeutics, Inc. (0001819411) (Subject)

    3/29/21 11:59:04 AM ET
    $GANX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GANX
    Leadership Updates

    Live Leadership Updates

    View All

    Gain Therapeutics Appoints Gene Mack as Chief Executive Officer and Director

    Gene Mack Has Served As CFO Since April 2024 And Interim CEO Since June 2024 Gianluca Fuggetta Will Assume The Role Of Senior Vice President, Finance BETHESDA, Md., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (NASDAQ:GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that Gene Mack, who has served as the Company's Chief Financial Officer since April 2024 and interim Chief Executive Officer since June 2024, has been appointed President and Chief Executive Officer, effective January 6, 2025. Mr. Mack has also been appointed as a me

    1/7/25 7:00:00 AM ET
    $GANX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Gain Therapeutics, Inc. Appoints Gene Mack as Interim CEO

    Mr. Mack is the Company's Current CFO Khalid Islam, PhD, Founder and Chairman of the Board, to serve as Executive Chairman BETHESDA, Md., June 27, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (NASDAQ:GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announces that Matthias Alder has departed the Company in order to pursue other opportunities. Upon Mr. Alder's departure, the Company appointed Gene Mack, the Company's current Chief Financial Officer, as interim Chief Executive Officer, effective June 25, 2024. Mr. Mack will retain his role as Chief Finan

    6/27/24 4:08:08 PM ET
    $GANX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Gain Therapeutics Bolsters Management Team with the Appointment of Gene Mack as Chief Financial Officer

    BETHESDA, Md., April 08, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (NASDAQ:GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announces the appointment of Gene Mack, MBA as its chief financial officer, effective as of April 8, 2024. "We are thrilled to welcome Gene as our new CFO," commented Gain CEO Matthias Alder. "His experience as an operational CFO with a track record of successful financing, M&A and other strategic transactions combined with his scientific background and career as an equity research analyst ideally complement our executive man

    4/8/24 9:25:00 AM ET
    $GANX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GANX
    Financials

    Live finance-specific insights

    View All

    Gain Therapeutics Reports Financial Results for First Quarter 2026 and Provides Corporate Update

    BETHESDA, Md., May 11, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (NASDAQ:GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today reported financial results for the quarter ended March 31, 2026, and provided a corporate update. "The first quarter of 2026 marked another exciting quarter for Gain, as we continued to build on the important advancements achieved in 2025 related to both the scientific understanding and clinical development of our lead candidate GT-02287, in development for the treatment of Parkinson's disease with or without a GBA1 mutation. This is

    5/11/26 7:00:00 AM ET
    $GANX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Gain Therapeutics Reports Financial Results for the Fourth Quarter and Year End 2025 and Provides Corporate Update

    BETHESDA, Md., March 26, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (NASDAQ:GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today reported financial results for the fourth quarter and year ended December 31, 2025, and provided a corporate update. "We are encouraged by the progress made in 2025, as we made important advancements related to both the scientific understanding and clinical development of our lead candidate GT-02287, in development for the treatment of Parkinson's disease with or without a GBA1 mutation. The promising impact GT-02287 has on the cau

    3/26/26 7:00:00 AM ET
    $GANX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Gain Therapeutics Reports Financial Results for First Quarter 2025 and Provides Corporate Update

    BETHESDA, Md., May 14, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (NASDAQ:GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today reported financial results for the quarter ended March 31, 2025, and provided a corporate update. "The first quarter of 2025 marked yet another exciting milestone for Gain with the first administration of GT-02287, our lead drug candidate in development for the treatment of Parkinson's disease (PD) with or without a GBA1 mutation, to participants with Parkinson's disease in our ongoing Phase 1b study which began enrollment in early M

    5/14/25 7:30:00 AM ET
    $GANX
    Biotechnology: Pharmaceutical Preparations
    Health Care